source
- Novartis CEO says shareholders remain supportive despite recent trial setbacksNovartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
- Three series-C funded biotechs expand hiring, including Triveni Bio’s $65 M raiseThree biotechnology companies that announced series C financing this year are actively hiring, signaling plans to scale operations. One of the firms secured a $140 million round and maintains offic…